Financial Performance - The company's revenue for Q3 2025 reached ¥260,745,815.74, representing a 15.02% increase year-over-year[7] - Net profit attributable to shareholders was ¥49,490,916.33, up 44.25% compared to the same period last year[7] - The basic earnings per share (EPS) was ¥0.46, reflecting a 43.75% increase year-over-year[7] - Total operating revenue for the current period reached ¥746,547,277.39, an increase of 16.5% compared to ¥641,129,724.80 in the previous period[30] - Net profit for the current period was ¥141,322,328.25, representing a 28.5% increase from ¥109,819,183.80 in the previous period[31] - Earnings per share (EPS) for the current period was ¥1.33, compared to ¥1.18 in the previous period, reflecting a growth of 12.7%[32] - The total comprehensive income for the current period was ¥142,853,221.19, compared to ¥111,505,906.50 in the previous period, reflecting a growth of 28.1%[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,376,655,547.04, a 3.88% increase from the end of the previous year[7] - The total current assets increased to CNY 1,974,561,740.45 from CNY 1,909,332,075.29, reflecting a growth of approximately 3.4%[27] - Total liabilities increased to ¥278,918,679.80, up from ¥245,319,949.37, indicating a growth of 13.7%[30] - Non-current assets totaled CNY 402,093,806.59, up from CNY 378,511,377.44, indicating an increase of approximately 6.2%[28] Cash Flow - The company reported a net cash flow from operating activities of ¥140,978,542.91, a significant increase of 134.39% compared to the previous year[17] - The net cash inflow from operating activities was $140,978,542.91, an increase from $60,147,840.11 in the previous period, reflecting a growth of approximately 134%[35] - Cash received from sales of goods and services was ¥744,469,203.55, an increase of 20.3% from ¥618,614,133.08 in the prior period[34] - The total cash inflow from operating activities was $790,990,375.24, compared to $632,637,592.61 in the previous period, marking an increase of approximately 25%[35] - The total cash outflow from operating activities was $650,011,832.33, up from $572,489,752.50, reflecting a rise of about 14%[35] - The ending cash and cash equivalents balance was $130,761,163.51, down from $1,446,822,796.05, indicating a significant reduction in liquidity[36] Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,851[19] - The largest shareholder, Tianjin Yuan Yi Enterprise Management Consulting Center, holds 17.91% of shares, totaling 19,082,000 shares[19] - Tianjin Wendi Enterprise Management Consulting Center holds 10.99% of shares, totaling 11,709,485 shares[19] - The foreign shareholder, Kangtuo Limited, holds 7.37% of shares, totaling 7,848,988 shares[19] - The top ten shareholders include several investment partnerships, with the largest being Tianjin Yuan Yi and Tianjin Wendi, both of which are domestic non-state-owned legal entities[20] - The total number of restricted shares at the end of the period is 19,082,000 for Tianjin Yuan Yi, with a lock-up period of 36 months from the date of listing[23] Research and Development - Research and development expenses increased by 45.33% to ¥47,963,600.69, driven by new product and technology development[15] - Research and development expenses for the current period were ¥47,963,600.69, up 45.3% from ¥33,002,325.33 in the previous period, highlighting increased investment in innovation[30] - The firm is focusing on new technology research and development to drive future growth and innovation[26] Investment Performance - Investment income surged by 544.51% to ¥15,495,868.92, primarily due to returns from joint ventures and cash management[15] - The company reported an investment income of ¥15,495,868.92, significantly higher than ¥2,404,271.60 in the previous period, indicating improved performance in investments[31] - The company received $2,747,367,000.00 from investment recoveries, a notable increase from $248,000,000.00 in the previous period[35] - The cash received from investment income was $10,320,609.08, compared to $1,983,302.61 previously, indicating a significant improvement in investment performance[35] Future Outlook - The company plans to enhance its market expansion strategies and product development initiatives in the upcoming quarters[26] - The management indicated a positive outlook for the next fiscal year, expecting continued revenue growth and improved profitability metrics[26] Other Information - The cash flow from financing activities decreased significantly by 106.74% to -¥51,955,274.00, mainly due to dividend payments[17] - The company did not conduct an audit for the third quarter financial report[37]

持股 5%以上股东苏州君联欣康创业投资合伙企业（有限合伙）和 HEALTH ADVANCE LIMITED 保证向本公司提供的信息内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"）于 2025 年 7 月 24 日在巨潮资讯网披露了《关于持股 5%以上股东减持股份预披露公告》（公告 编号：2025-027）（以下简称"本次减持计划"）。公司持股 5%以上股东苏州 君联欣康创业投资合伙企业（有限合伙）（以下简称"君联欣康"）以及康拓有 限公司（HEALTH ADVANCE LIMITED）（以下简称"HAL"）计划自上述公 告披露之日起 15 个交易日之后 3 个月内通过集中竞价或大宗交易方式减持公司 股份，减持数量合计不超过 3,196,930 股（占公司总股本的 3.0000%）。其中， 通过集中竞价方式减持不超过 1,065,640 股（占公司总股本的 1.0000%），通过 大宗交易方式减持不超过 2,131,290 股（占公司总股本的 2.0000%）。 证券 ...

董秘最新回复 投资者： 你好董秘，截止2025年10月20号股东总数为多少？ 董秘： 尊敬的投资者，您好。公司将会按照证监会、深交所的相关规定在定期报告中披露股东人数， 敬请关注公司相关公告。您也可将有效持股证明文件发送至公司官方邮箱，公司核实投资者身份后予以 回复。谢谢！ 截至2025年10月21日收盘，爱迪特(301580)报收于44.4元，上涨2.12%，换手率1.49%，成交量1.07万 手，成交额4721.98万元。 当日关注点 交易信息汇总资金流向 10月21日主力资金净流入394.75万元；游资资金净流出481.78万元；散户资金净流入87.03万元。 大宗交易 10月21日爱迪特发生5笔大宗交易，合计成交2180.31万元，平均折价10.88%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：10月21日主力资金净流入394.75万元，显示主力对个股短期态度偏积极。 来自交易信息汇总：爱迪特当日发生5笔大宗交易，合计成交2180.31万元，折价率达10.88%。 ...

证券代码： 301580 证券简称：爱迪特 公告编号： 2025-049 爱迪特（秦皇岛）科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 3、交流内容：公司将针对 2025 年第三季度经营成果、财务指标等与投资 者进行交流，并对投资者普遍关注的问题进行回答。 4、出席人员：董事长、总经理李洪文先生；董事会秘书、副总经理郜雨女 士；财务总监孔祥乾先生。（具体以当天实际参会人员为准） 5、报名及参会方式： （1）网络端报名参会：https://s.comein.cn/pu7mywyc （2）手机端报名参会：登陆进门财经 APP/进门财经小程序，搜索 "301580"或"爱迪特"进入"爱迪特（301580）2025 年第三季度业绩说明 会"；或扫描下方二维码报名参会： （3）电话参会（需提前通过上述方式报名参会） 爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"）将于 2025 年 10 月 29 日在巨潮资讯网（www.cninfo.com.cn）披露《2025 年第三季度报告》。 为加强与投资者 ...

证券日报网讯爱迪特（301580）10月16日在互动平台回答投资者提问时表示，公司产品凭借自身优势， 获得了海外市场认可，国外合同预计将保持良好的增长态势。 ...

证券日报网讯爱迪特（301580）10月14日在互动平台回答投资者提问时表示，2025年上半年公司在境外 的营业收入为3.27亿元，同比增长34.41%。欧洲是公司重要市场之一，经过多年品牌和渠道建设，凭借 优质的产品和服务，已经与多家行业头部客户达成了稳定合作，公司有信心在欧洲市场持续提升覆盖率 和渗透率，保持较强的竞争力。 ...

证券日报网讯爱迪特（301580）10月14日在互动平台回答投资者提问时表示，公司已通过成熟供应链合 作、配方优化及多渠道布局，有效对冲成本波动风险，保障生产经营稳定。氧化钇的具体市场价格因采 购场景、规模不同存在差异且实时变动，若出现对公司业绩有重大影响的价格变动，公司将按规则通过 法定渠道披露。 ...

Core Viewpoint - The company's performance in the first half of 2025 meets expectations, with strong growth in overseas business. Looking ahead to Q3 and the second half of 2025, the company is actively expanding its overseas market, expecting foreign income to maintain rapid growth. In the domestic market, the company anticipates that the revenue growth rate will exceed that of 2024 through the synergistic development of chairside repair systems, implant business, and repair materials [1][4][6]. Financial Performance - In the first half of 2025, the company achieved revenue of 486 million yuan, a year-on-year increase of 17.22%, and a net profit attributable to shareholders of 92 million yuan, up 19.86%. The net profit excluding non-recurring items was 84 million yuan, reflecting a growth of 9.35% [2][4]. - For Q2 2025, the company reported revenue of 280 million yuan, a year-on-year increase of 16.61% and a quarter-on-quarter increase of 36.52%. The net profit attributable to shareholders was 61 million yuan, up 13.61% year-on-year and 94.34% quarter-on-quarter [4]. Business Segments - The core business of dental repair materials showed steady growth, with revenue of 358 million yuan in the first half of 2025, a year-on-year increase of 19.19%, accounting for 73.74% of total revenue. The revenue from digital dental equipment was 96 million yuan, up 3.64% year-on-year, representing 19.80% of total revenue [5]. - The overall gross margin for the first half of 2025 was approximately 51.94%, slightly down year-on-year. The gross margin for dental repair materials was 58.20%, down 2.17 percentage points, while the gross margin for digital dental equipment was 30.50%, up 1.24 percentage points [5]. Research and Development - The company increased its R&D investment, with R&D expenses reaching 28 million yuan, a year-on-year increase of 36.12%, representing 5.82% of revenue. This increase is attributed to the hiring of additional R&D personnel and higher costs for new product registrations [6]. Strategic Outlook - The company aims to consolidate its leading position in the dental repair materials sector and build long-term competitiveness through a "materials + equipment + implants" collaborative development strategy [7][8]. - The company is enhancing its global layout, with overseas markets becoming a significant driver of revenue growth, as evidenced by a 34% year-on-year increase in foreign income in the first half of 2025 [9]. Revenue Forecast - The company forecasts revenues of 1.034 billion yuan, 1.205 billion yuan, and 1.407 billion yuan for 2025, 2026, and 2027, respectively, representing year-on-year increases of 16.4%, 16.56%, and 16.73%. The net profit attributable to shareholders is projected to be 180 million yuan, 217 million yuan, and 262 million yuan for the same years, with growth rates of 19.33%, 20.73%, and 20.78% [10].

爱迪特（301580.SZ）9月29日在投资者互动平台表示，公司2025年第三季度报告预计于2025年10月29日 披露，具体经营情况请以公司届时发布的定期报告为准。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：贵司三季度业绩什么时候披露？有增长的预期么？ ...

中信建投证券股份有限公司 关于爱迪特（秦皇岛）科技股份有限公司 股东向特定机构投资者询价转让股份的核查报告 深圳证券交易所： 中信建投证券股份有限公司（以下简称"中信建投证券"或"组织券商"） 受委托担任 Schroders Capital Private Equity Asia Hong Kong I Limited（以下简称 "出让方"）以向特定机构投资者询价转让（以下简称"询价转让"）方式减 持所持有的爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"或"爱迪 特"）首次公开发行前已发行股份的组织券商。 经核查，组织券商就本次询价转让的股东、受让方是否符合《深圳证券交 易所上市公司自律监管指引第 16 号——创业板上市公司股东询价和配售方式转 让股份（2025 年修订）》（以下简称"《询价转让和配售指引》"）要求，本 次询价转让的询价、转让过程与结果是否公平、公正，是否符合《询价转让和 配售指引》的规定作出如下报告说明。 一、本次询价转让概况 （一）本次询价转让出让方 截至 2025 年 9 月 17 日，出让方所持公司首发前股份的数量及占公司总股 本比例情况如下： | 1 | Schroders | ...